Home Forums Other Specialities Cardiothoracic Medicine & Surgery IVABRADINE- In LVdysfunction with Coronary Artery Disease

Viewing 0 reply threads
  • Author
    Posts
    • #1674
      Anonymous
      Inactive

      Aims To test the effect of ivabradine on the outcomes in a broad population with left-ventricular (LV) systolic dysfunction with coronary artery disease (CAD) and/or heart failure (HF).

      Methods and results

      Individual trial data from BEAUTIFUL and SHIFT were pooled to evaluate the effect of ivabradine on the outcomes in patients with LV dysfunction and heart rate ?70 b.p.m. The pooled population (n = 11 897; baseline age 62.3 ± 10.4 years, heart rate 79.6 ± 9.2 b.p.m., and LV ejection fraction 30.3 ± 5.6%) was well treated according to current recommendations (87% beta-blockers, 90% renin–angiotensin system inhibitors). Median follow-up was 21 months. Treatment with ivabradine was associated with a 13% relative risk reduction for the composite of cardiovascular mortality or HF hospitalization (P < 0.001 vs. placebo); this was driven by HF hospitalizations (19%, P < 0.001). There were also significant relative risk reductions for the composite of cardiovascular mortality, HF hospitalizations, or myocardial infarction (MI) hospitalization (15%, P < 0.001); cardiovascular mortality and non-fatal MI (10%, P = 0.023); and MI hospitalization (23%, P = 0.009). Similar results were found in patients with differing clinical profiles. Ivabradine was well tolerated. Conclusion Ivabradine may be important for the improvement of clinical outcomes in patients with LV systolic dysfunction and heart rate ?70 b.p.m., whatever the primary clinical presentation (CAD or HF) or clinical status (NYHA class). ref- European heart Journal- April 2013 G.Mohan

Viewing 0 reply threads
  • You must be logged in to reply to this topic.